87 related articles for article (PubMed ID: 17306439)
1. Editorial comment on: Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells.
Schalken J
Eur Urol; 2007 Dec; 52(6):1679. PubMed ID: 17306439
[No Abstract] [Full Text] [Related]
2. Editorial comment on: Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells.
Edwards J; Leung HY
Eur Urol; 2007 Dec; 52(6):1680-1. PubMed ID: 17306442
[No Abstract] [Full Text] [Related]
3. Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells.
Paju A; Hotakainen K; Cao Y; Laurila T; Gadaleanu V; Hemminki A; Stenman UH; Bjartell A
Eur Urol; 2007 Dec; 52(6):1670-9. PubMed ID: 17306443
[TBL] [Abstract][Full Text] [Related]
4. Tumour-associated trypsin inhibitor and tumour-associated trypsin.
Stenman UH
Scand J Clin Lab Invest Suppl; 1990; 201():93-101. PubMed ID: 2244188
[TBL] [Abstract][Full Text] [Related]
5. [Clinical evaluation of tumor-associated trypsin inhibitor (TATI) in benign and malignant gynecological tumor].
Shigemasa K; Hiura M; Ioka A; Yokoyama T; Nogawa T; Chiba T
Nihon Sanka Fujinka Gakkai Zasshi; 1993 Mar; 45(3):256-7. PubMed ID: 8492013
[No Abstract] [Full Text] [Related]
6. [Significance of the the tumor markers, Ca-125 and tumor-associated trypsin inhibitor in patients with carcinoma of the cervix and uterus].
Ilić RS; Mihailović D
Srp Arh Celok Lek; 1992; 120(3-4):97-9. PubMed ID: 1465666
[TBL] [Abstract][Full Text] [Related]
7. Autocrine induction of invasion and metastasis by tumor-associated trypsin inhibitor in human colon cancer cells.
Gouyer V; Fontaine D; Dumont P; de Wever O; Fontayne-Devaud H; Leteurtre E; Truant S; Delacour D; Drobecq H; Kerckaert JP; de Launoit Y; Bracke M; Gespach C; Desseyn JL; Huet G
Oncogene; 2008 Jul; 27(29):4024-33. PubMed ID: 18317448
[TBL] [Abstract][Full Text] [Related]
8. [Determination of tumor-associated trypsin inhibitor (TATI) in subjects with gastrointestinal diseases. Preliminary data].
Piantino P; Mosso R; Polloni R; Cerchier A; Gennaretti G; Daziano E
Minerva Med; 1989 Mar; 80(3):199-203. PubMed ID: 2717042
[TBL] [Abstract][Full Text] [Related]
9. Tumour-associated trypsin inhibitor, TATI. Clinical use and biological function.
Stenman UH; Koivunen E; Itkonen O; Turpeinen U; Halila H; Huhtala ML
Ann Chir Gynaecol; 1989; 78(1):77-82. PubMed ID: 2667452
[No Abstract] [Full Text] [Related]
10. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.
Gkialas I; Papadopoulos G; Iordanidou L; Stathouros G; Tzavara C; Gregorakis A; Lykourinas M
Urology; 2008 Nov; 72(5):1159-63. PubMed ID: 18514770
[TBL] [Abstract][Full Text] [Related]
11. Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis.
Diallo JS; Aldejmah A; Mouhim AF; Fahmy MA; Koumakpayi IH; Sircar K; Bégin LR; Mes-Masson AM; Saad F
BJU Int; 2008 May; 101(10):1302-9. PubMed ID: 18294307
[TBL] [Abstract][Full Text] [Related]
12. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers.
Sardana G; Jung K; Stephan C; Diamandis EP
J Proteome Res; 2008 Aug; 7(8):3329-38. PubMed ID: 18578523
[TBL] [Abstract][Full Text] [Related]
13. [Protease inhibitors as tumor-associated growth factors].
Hochstrasser K; Reisinger PW; Albrecht GJ; Wustrow TP
Laryngorhinootologie; 1989 Jan; 68(1):51-6. PubMed ID: 2464731
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the prognostic value of a panel of tissue tumor markers and established clinicopathological factors in patients with gastric cancer.
Wiksten JP; Lundin J; Nordling S; Kokkola A; Haglund C
Anticancer Res; 2008; 28(4C):2279-87. PubMed ID: 18751407
[TBL] [Abstract][Full Text] [Related]
15. Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer.
Horvath LG; Lelliott JE; Kench JG; Lee CS; Williams ED; Saunders DN; Grygiel JJ; Sutherland RL; Henshall SM
Prostate; 2007 Jul; 67(10):1081-90. PubMed ID: 17476687
[TBL] [Abstract][Full Text] [Related]
16. Dystroglycan expression is reduced during prostate tumorigenesis and is regulated by androgens in prostate cancer cells.
Sgambato A; De Paola B; Migaldi M; Di Salvatore M; Rettino A; Rossi G; Faraglia B; Boninsegna A; Maiorana A; Cittadini A
J Cell Physiol; 2007 Nov; 213(2):528-39. PubMed ID: 17516554
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines.
Pignon JC; Koopmansch B; Nolens G; Delacroix L; Waltregny D; Winkler R
Cancer Res; 2009 Apr; 69(7):2941-9. PubMed ID: 19318561
[TBL] [Abstract][Full Text] [Related]
19. Stromal anti-apoptotic androgen receptor target gene c-FLIP in prostate cancer.
Ye H; Li Y; Melamed J; Pearce P; Wei J; Chiriboga L; Wang Z; Osman I; Lee P
J Urol; 2009 Feb; 181(2):872-7. PubMed ID: 19095249
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of Bcl-2 is required for the progression of prostate cancer cells from an androgen-dependent to an androgen-independent growth stage.
Lin Y; Fukuchi J; Hiipakka RA; Kokontis JM; Xiang J
Cell Res; 2007 Jun; 17(6):531-6. PubMed ID: 17404601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
